NewsRoom Articles - Page 185 of 226

WednesdayMar 03, 2021 12:15 pm

Hydrogel Injection Could Change Cardiac Tissue Healing After Heart Attacks

Researchers at Spain’s University of Valladolid, BIOFORGE Labs, the SFI Research Center and CÚRAM have created a hydrogel injectable that may prevent additional damage and assist in repairing heart muscles following a heart attack. Heart disease, or myocardial infarction, is the most common cause of death owing to irreversible damage of cardiac tissue after a heart attack. As tissue regeneration is minimal, any damage to heart muscle can’t be self-repaired. Present-day treatments lack an efficacious way to improve heart muscle repair and prevent death after a heart attack. The project’s lead, Professor Abhay Pandit, scientific director of CÚRAM, explained that…

TuesdayMar 02, 2021 2:57 pm

United Medical Equipment Business Solutions Network Inc. Stands to Benefit as Health Officials Call for More at Home Testing

Testing is more important than ever, medical experts claim, urging government to speed up widespread testing Tens of millions of rapid, at-home tests may be needed every day UME offers rapid testing kits to help end the pandemic, ready to seize the opportunity The U.S. government has announced plans to roll out more than 60 million home test kits to stop the COVID-19 virus from spreading (https://ibn.fm/O89KJ). United Medical Equipment Business Solutions Network (“UME”), a company offering a comprehensive line of COVID-19 products including rapid testing kits, stands ready to capitalize on the growing push for widespread testing and help…

TuesdayMar 02, 2021 2:13 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic About Upcoming Berubicin Trials After IND Approval

Berubicin is CNS Pharmaceuticals’ lead product candidate for treatment of Glioblastoma Multiforme, and has the potential to be the first anthracycline to cross the blood-brain barrier based on limited results from a Phase 1 trial The market for GBM treatment is estimated to reach $3.3 billion in 2024, growing at a CAGR of 17.4% CNS, in collaboration with sublicensee partner WPD Pharmaceuticals, is currently planning three Berubicin clinical trials, all to start within the year – two Phase II adult trials and a pediatric Phase I trial Glioblastoma Multiforme (“GBM”) is one of the most aggressive forms of brain cancer…

TuesdayMar 02, 2021 11:11 am

Researchers Find That Lower Temperatures Boost Coronavirus Transmission

The coronavirus pandemic has affected many industries and economies worldwide, in addition to causing the deaths of more than 500,000 people in America and 2.3-plus million people globally. Understanding how seasonal temperature changes affect virus transmission is crucial in decreasing the spread of the virus in the future. The virus that causes the coronavirus, SARS-CoV-2, is part of a larger coronavirus family, which aren’t spread as easily in warmer parts and during humid times in the year. Instead, the spread of these viruses increases in less humid times in cooler places. With this information in mind, researchers from the Joint…

MondayMar 01, 2021 2:15 pm

Pandemic Worsens ADHD in Kids, Experts Fear

Maggie Sibley, a clinical psychologist at the Center for Child Health, Behavior and Development at Seattle Children’s Research Institute, is worried about the effect the coronavirus pandemic has had on adolescents and children with hyperactivity/attention-deficit disorder as well as children experiencing depression and teens who may drop out of high school — and with good reason. Last year was difficult for many people, and perhaps more so for individuals who struggle with mental health and neurodevelopmental issues. Sibley explained that there were a lot more risk factors that may cause depression, adding that individuals with ADHD were at a higher…

FridayFeb 26, 2021 1:50 pm

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Releases Record-Breaking Gross Revenue for January 2021

Company reports record gross revenues of C$1,089,502 last month “It is truly encouraging to achieve yet another incredible revenue milestone and to start the new year with such vigor and success,” states CEO Record revenue comes during one of slowest e-commerce periods of year, highlighting impact the company has in the plant-based marketplace PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) saw record gross revenues last month (https://ibn.fm/qro4v). The company released its monthly numbers, noting that gross revenues for January 2021 totaled a record-breaking C$1,089,502; cost of goods sold for the month reached C$751,356. “It is truly encouraging to achieve yet…

FridayFeb 26, 2021 1:37 pm

Predictive Oncology Inc. (NASDAQ: POAI) Receives ‘Buy’ Rating from Litchfield Hills Research in First Analyst Coverage Report

Calling POAI undervalued, Litchfield initiates coverage of Predictive Oncology with Buy rating, $3 price target The drug industry is changing as tools and technology to tailor drugs emerge, regulatory bodies focus on patients’ experiences, perspectives, needs Litchfield report notes several POAI strengths under “Investment Thesis” section A growing number of companies and health providers alike are paying attention to what the FDA is calling patient-focused drug development (“PFDD”), a systematic approach to help ensure that patients’ experiences, perspectives, needs and priorities are captured and meaningfully incorporated into drug development and evaluation. In that growing market, Predictive Oncology (NASDAQ: POAI), a…

FridayFeb 26, 2021 12:15 pm

Research on Sensitive Blood Test for Cancer Wins 2021 Top-10 Award

The Clinical Research Forum recently awarded cancer biologists from Weill Cornell Medicine its Top-10 Clinical Research Achievement Award for their 2020 study that described a sensitive blood test for detecting a cancer relapse or the disease’s progression. The findings of the study were reported in “Nature Medicine.” The group of researchers was led by associate professor of medicine, Dr. Dan Landau, who is also a member of the Sandra and Edward Meyer Cancer Center. The study’s first author was Dr. Asaf Zviran, a postdoctoral researcher in Landau’s laboratory. The model developed in their study utilizes DNA whole-genome sequencing of a…

FridayFeb 26, 2021 12:13 pm

Better Cancer Outcomes Possible with Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Technology

Imagin Medical Inc.’s patented i/Blue System revolutionizes the way surgeons are able to visualize the bladder and identify cancers during surgery The breakthrough technology of Imagin Medical’s i/Blue Imaging System rectifies the limitations of both white and blue light cystoscopies Bladder cystoscopies first target - multiple other endoscopic procedures planned Science and technology have continued to make striking advancements in cancer therapeutics and treatment protocols, improving upon on past successes and creating better outcomes for cancer patients. A prime example is an exciting new development in visualizing cancer during minimally invasive surgeries. Surgical imaging company Imagin Medical (CSE: IME) (OTCQB:…

ThursdayFeb 25, 2021 2:45 pm

Study Discovers That Protein Imbalance May Cause Cataracts

Cataracts are a common eye disease, and while researchers have yet to fully understand how the disease works, plenty of research has been done on this ailment. Recently, a group of researchers at the Technical University of Munich (“TUM”) found that the composition of the protein solution was a factor in the disease. The researchers’ findings go against the field’s popular opinion. TUM’s chair of biotechnology Prof. Johannes Buchner explained that the cells in an eye lens are comprised of a protein solution that is highly concentrated and normally clear. However, he continued, a protein imbalance may cause the proteins to…